HIGH IMPACT – Small Pharma announced that the United States Patent and Trademark Office (USPTO) will be issuing a patent for its application pertaining to novel injectable formulations of N,N-dimethyltryptamine (DMT) based compounds including the company’s lead assets, SPL026 (DMT) and SPL028 (deuterated DMT). Additionally, the patent also covers novel injectable formulations of other known psychedelic compounds, including 5-methoxy-DMT and psilocybin.
The USPTO will issue the patent on August 9th, 2022 and the patent will provide protection until August 2041. This is the company’s first US patent, although it will be the ninth patent to be granted overall.
Several psychedelic therapeutics are in the pipeline for mood and anxiety disorders with results thus far encouraging. With the increasing competitive threat, the convenience of administration will be an important differentiator.
Small Pharma is currently investigating an IV formulation of its lead DMT asset, SPL026, in major depressive disorder in the UK in a Phase 1/2a study with results expected in Q4 2022. The company plans to initiate a bridging study comparing SPL026 IV and IM formulations in H2 2022.
Source: Small Pharma Press Release